In conclusion, our study show that Myr treatment ameliorated inflammatory responses and the aggressive phenotype of RA FLSs, reducing AIM2 expression, sequentially inhibiting AKT phosphorylation. The gene discussed is AKT1; the disease is rheumatoid arthritis.